Exploring correlations between changes in lymphocyte counts and clinical/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: analyses from the double-blind, 96-week CLARITY study

被引：0
|
作者：
Rieckmann, P.
Sorensen, P. Soelberg
Comi, G.
Cook, S.
Giovannoni, G.
Rammohan, K.
Vermersch, P.
Kurukulasuriya, N.
Bock, D.
Greenberg, S.
机构：
[1] Bamberg Acad Hosp, Bamberg, Germany
[2] Univ Copenhagen Hosp, DK-2100 Copenhagen, Denmark
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Med, Newark, NJ USA
[5] Barts & London Queen Marys Sch Med & Dent, London, England
[6] Univ Miami, Miami, FL USA
[7] Univ Lille, Lille, France
[8] Univ Erlangen Nurnberg, Erlangen, Germany
[9] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：48 / 48
页数：1
相关论文
共 50 条
  • [1] Investigating the Relationship Between Cladribine-Mediated Changes in Lymphocyte Counts and Clinical/Magnetic Resonance Imaging Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis: Correlation Analyses from the Double-Blind, 96-week CLARITY Study
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Vermersch, Patrick
    Kurukulasuriya, Nuwan C.
    Bock, Daena
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A133 - A134
  • [2] Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S136 - S137
  • [3] Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S49 - S50
  • [4] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 215 - 215
  • [5] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S21 - S21
  • [6] Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study
    Giovannoni, Gavin
    Cami, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Veriee, Rehan
    Musch, Bruno
    Greenberg, Steven
    NEUROLOGY, 2010, 74 (09) : A295 - A296
  • [7] Consistent efficacy of cladribine tablets across the spectrum of patients with relapsing-remitting multiple sclerosis of differing severity: data from the 96-week, double-blind CLARITY study
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Bock, D.
    Hamlett, A.
    Viglietta, V.
    Musch, B.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 56 - 56
  • [8] Relapses and lymphocyte counts before and after rescue therapy in the phase III, 96-week, double-blind, placebo-controlled CLARITY study of cladribine tablets for relapsing-remitting multiple sclerosis
    Sorensen, P. Soelberg
    Giovannoni, G.
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Vermersch, P.
    Kurukulasuriya, N.
    Hamlett, A.
    Galazka, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S411 - S411
  • [9] Effects of Cladribine Tablets on Circulating Lymphocyte Subset Reconstitution in the 96-Week CLARITY Study in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Soelberg, Per
    Rieckmann, Peter
    comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Vermersch, Patrick
    Bock, Daena
    Hamlett, Anthony
    Fevr, Tea
    Musch, Bruno
    Greenberg, Steve
    NEUROLOGY, 2010, 74 (09) : A372 - A372
  • [10] Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis
    Sorensen, P. Soelberg
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Vermersch, P.
    Bock, D.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S143 - S143
12345